menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    PTC Therapeutics to Participate in Upcoming Investor Conferences

    PR NEWSWIRE

    FDA Priority Review To PTC’s Vatiquinone For Friedreich’s Ataxia

    PR NEWSWIRE

    PTC Therapeutics to Call to Discuss Q4 & Full Year 2024 Results

    PR NEWSWIRE

    Orsini Named Exclusive Provider For KEBILIDI™ Gene Therapy

    PR NEWSWIRE

    PTC Therapeutics Updates On R&D Pipeline At J.P. Morgan Conference

    PR NEWSWIRE

    PTC Therapeutics Reports Inducement Grants Under Nasdaq LR 5635©

    PR NEWSWIRE

    PTC Therapeutics to Present at 43rd J.P. Morgan Health Conference

    PR NEWSWIRE

    PTC Therapeutics Submits Vatiquinone NDA for Friedreich Ataxia

    PR NEWSWIRE

    PTC Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    PR NEWSWIRE

    PTC Therapeutics signs up to $2.9 B licensing deal with Novartis

    REUTERS

    PTC Therapeutics to Sell Priority Review Voucher for $150 Million

    PR NEWSWIRE

    PTC Therapeutics discontinues ALS drug after trial failure

    REUTERS

    PTC Therapeutics Reports Inducement Grants Under Nasdaq 5635(c)(4)

    PR NEWSWIRE

    FDA approves PTC Therapeutics` gene therapy for ultra-rare disorder

    REUTERS

    PTC Reports Q3 2024 Financials & Corporate Update

    PR NEWSWIRE

    PTC Therapeutics to Participate at Upcoming Investor Conferences

    PR NEWSWIRE

    PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA

    PR NEWSWIRE

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Rule

    PR NEWSWIRE

    PTC Therapeutics To Host Q3 2024 Results Conference Call

    PR NEWSWIRE

    Europe`s CHMP backs Novo`s FDA-rejected hemophilia treatment

    FIERCE PHARMA

    CHMP Maintains Negative Opinion on Translarna™ Reexamination

    PR NEWSWIRE

    PTC Therapeutics Announces FDA Date For Sepiapterin

    PR NEWSWIRE

    PTC bounces back with positive data on FA prospect vatiquinone

    FIERCE BIOTECH

    PTC Announces Positive Results For Vatiquinone Ataxia Program

    PR NEWSWIRE

    PTC Therapeutics` NDA for Sepiapterin Accepted for Phenylketonuria

    PR NEWSWIRE

    FDA Grants Fast Track To PTC518 For Huntington`s

    PR NEWSWIRE

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PR NEWSWIRE

    PTC Therapeutics to Participate at Upcoming Investor Conferences

    PR NEWSWIRE

    PTC Therapeutics Reports Q2 2024 Results And Corporate Update

    PR NEWSWIRE

    PTC Therapeutics To Host Q2 2024 Financial Results Call

    PR NEWSWIRE

    EU`s drug regulator again rejects Apellis` eye med and PTC`s Translarna

    FIERCE PHARMA

    CHMP Issues Negative Opinion On Translarna Following European Commission Review

    PR NEWSWIRE

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PR NEWSWIRE

    PIVOT-HD Shows Positive 12-Month Biomarker And Clinical Data In Huntington`s

    PR NEWSWIRE

    PTC Therapeutics to Participate at Upcoming Investor Conference

    PR NEWSWIRE

    PTC Therapeutics Announces Validation of Sepiapterin European MAA

    PR NEWSWIRE

    PTC gets another chance to keep Translarna`s EU authorization

    FIERCE PHARMA

    PTC: EU Returns Translarna Opinion To CHMP For Re-Evaluation

    PR NEWSWIRE

    PTC Announces FDA Acceptance, Priority Review Of Upstaza BLA

    PR NEWSWIRE

    PTC Therapeutics to Participate at Upcoming Investor Conferences

    PR NEWSWIRE

    Technical Analysis of PTC Therapeutics

    TRADINGVIEW

    PTC Therapeutics Q1 2024 Results, Corporate Update

    PR NEWSWIRE

    PTC Therapeutics Inducement Grants Under Nasdaq 5635(c)(4)

    PRESS RELEASE

    PTC Therapeutics To Host Q1 2024 Results Call

    PR NEWSWIRE

    PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

    PR NEWSWIRE

    PTC Therapeutics Provides Key Regulatory Updates

    PR NEWSWIRE

    ClearPoint Congratulates its Partner PTC of BLA Sub to FDA for Upstaza

    GLOBENEWSWIRE

    After pair of failures, PTC finds path for Friedreich ataxia med

    FIERCE BIOTECH

    PTC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    PRESS RELEASE

    PTC Therapeutics to Participate at Upcoming Investor Conferences

    PR NEWSWIRE

    PTC to Host Conference to Discuss Q4 and Full Year 2023 Financial Results

    PR NEWSWIRE

    PTC`s Emflaza to face generics this month post Aurobindo FDA nod

    FIERCE PHARMA

    PTC`s re-examination bid for Translarna falls short in Europe

    FIERCE PHARMA

    PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline

    PR NEWSWIRE

    PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Conference

    PR NEWSWIRE

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PR NEWSWIRE

    PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

    PR NEWSWIRE

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PR NEWSWIRE

    FDA demands data on 2 PTC candidates, delaying filing

    FIERCE BIOTECH

    PTC Therapeutics Reports Third Quarter Financial Results

    PR NEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.